High expression of Ang2 in malignant tissue correlates with poor survival rate, and/or high frequency of metastasis, and/or high microvascular density (MVD) in patients with advanced colorectal carcinoma, breast cancer, gastric carcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), prostate cancer, and ovarian cancer [38-47]. Here, ANGPT2 is linked to ovarian carcinoma.